PTHS

Pelthos Therapeutics Inc. (PTHS) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2025. Pelthos Therapeutics Inc. (formerly Channel Therapeutics Corporation) is a clinical-stage biotech company focused on developing non-opioid pain therapeutics targeting the NaV1.7 sodium ion-channel. The company operates as a single reportable segment. As of the reporting date, the company had not generated revenue from product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2025, increased by 37% ($1.37 million) compared to the same period in 2024. This was driven primarily by a 76% increase in professional fees (due to merger-related legal and accounting costs) and a 48% increase in R&D expenses (primarily Chemistry, Manufacturing, and Controls costs).
• Liquidity Deterioration: Cash balances declined from $513,443 at year-end 2024 to $59,172 at June 30, 2025. The working capital deficit widened significantly from $2.7 million to $6.5 million.
• Debt Position: Current liabilities increased by approximately $3.2 million year-over-year, largely due to the issuance of bridge notes (February, May, and June 2025) and accrued expenses. Several notes payable were in default as of June 30, 2025, though no formal notices of default had been received from holders.
• Stock-Based Compensation: Stock-based compensation expense increased to $899,317 for the six months ended June 30, 2025, compared to $751,530 in the prior year period.

Outlook, Risks, and Subsequent Events

Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least twelve months following the issuance of these financial statements, citing the need for additional capital to fund operations and clinical trials.

Subsequent Events (Post-June 30, 2025):

• Merger and Name Change: On July 1, 2025, the company consummated a merger with LNHC, Inc. (a subsidiary of Ligand Pharmaceuticals). The company changed its name from Channel Therapeutics Corporation to Pelthos Therapeutics Inc. and adopted the ticker symbol "PTHS".
• Reverse Stock Split: A 10-for-1 reverse stock split was effected on July 1, 2025.
• PIPE Financing: Concurrent with the merger, the company completed a PIPE financing raising approximately $50.1 million (including $50.0 million in cash) through the issuance of Series A Convertible Preferred Stock. Ligand Pharmaceuticals invested $18 million as part of this round.
• Acquisition of Zelsuvmi: The merger acquired LNHC, which holds the FDA-approved topical treatment Zelsuvmi for molluscum contagiosum. The company entered into royalty agreements regarding Zelsuvmi and its existing pipeline products.
• Legal Proceedings: The company obtained a default judgment in the "Kopfli Matter" on July 25, 2025, awarding damages of approximately $18.3 million against a former executive and Chromocell Holdings. A demand letter was also received from a former Chief Medical Officer regarding potential liability of up to $1 million.

Investor Verification Checklist

• Capital Adequacy: Verify the status of the $50.1 million PIPE financing proceeds and their impact on the company's liquidity position post-merger.
• Debt Obligations: Confirm the repayment status of the bridge notes and the May Promissory Note that were in default as of June 30, 2025.
• Merger Integration: Review the terms of the royalty agreements (Zelsuvmi and Channel Products) and the extent of Ligand Pharmaceuticals' ownership and control post-merger.
• Legal Risks: Assess the collectability of the $18.3 million judgment in the Kopfli Matter and the potential exposure from the Lang Demand Letter.
• Stock Structure: Confirm the post-split share count and the conversion terms of the Series A Preferred Stock issued in the PIPE financing.